Yep. If in CIBMTR's shoes, the FDA looked at the new assay data and said the evidence ( now ) can support approval. That is a vastly different tone to the FDA's do not start any more trials until potency is adequate, or you gather more data from additional trials.
Yep. If in CIBMTR's shoes, the FDA looked at the new assay data...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
-0.010(0.92%) |
Mkt cap ! $1.227B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.11 | $1.06 | $3.197M | 2.961M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 23475 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 24311 | 2 |
View Market Depth
| Last trade - 16.10pm 20/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.07 |
Change
-0.010 ( 2.21 %) |
||||
| Open | High | Low | Volume | ||
| $1.10 | $1.11 | $1.06 | 777974 | ||
| Last updated 15.59pm 20/05/2024 ? | |||||
| MSB (ASX) Chart |